Canada Drug for Prophylactic Human Papillomavirus Vaccines - Forecast to 2022

Order report by calling at +1 888 391 5441 OR send an email on with (PharmaPoint: Prophylactic Human Papillomavirus Vaccines - Canada Drug Forecast and Market Analysis to 2022) / report name in subject line and your contact details.


The first prophylactic vaccine for immunization against human papillomavirus (HPV) became available in 2006. The global HPV vaccines market is now well established, yet vaccine coverage rates amongst the traditional target population of adolescent girls remain persistently low. Initially HPV vaccines were developed and marketed solely to protect against cervical cancer. In recent years the role of HPV in other cancers has been increasingly recognized which has facilitated a shift towards vaccinating a wider population, most significant has been the inclusion of males in routine vaccine recommendations in some countries. The current HPV vaccines market is dominated by one major player, Merck's Gardasil, with GlaxoSmithKline's (GSK's) HPV vaccine Cervarix providing the only competition. The introduction of Merck's nine-valent vaccine (V503) is set to change the future landscape of the HPV vaccines sector.

The anticipated addition of boys to routine HPV vaccine recommendations by different Canadian provinces is expected to serve as a significant driver to growth within the HPV vaccines market in Canada over the forecast period. In addition, from primary research insight, GlobalData projects Merck's nine-valent vaccine V503 to be widely adopted in the country. This will also significantly enhance the size of the HPV vaccines sector in Canada.


Complete report is available @ .



  • Overview of Prophylactic Human Papillomavirus Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in the Canada including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in the Canada from 2012-2022.
  • Analysis of the impact of key events as well the drivers and restraints affecting the Canada Prophylactic Human Papillomavirus Vaccines disease market.


Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Prophylactic Human Papillomavirus Vaccines
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2012-2022 in the Canada


Request a sample of this report @  .


List of Tables

Table 1: Histological Progression Towards Cervical Cancer 14
Table 2: Diseases Associated with HPV Infection and Their Associated Symptoms 16
Table 3: Routine HPV Vaccine Programs by Province, Canada 18
Table 4: Marketed Vaccines for HPV, 2014 24
Table 5: Product Profile - Gardasil 26
Table 6: Phase III Efficacy Trials - Gardasil 28
Table 7: Safety Profile - Gardasil 29
Table 8: Gardasil SWOT Analysis, 2014 29
Table 9: Product Profile - Cervarix 31
Table 10: Phase III Efficacy Trials - Cervarix 32
Table 11: Safety Profile - Cervarix 33
Table 12: Cervarix SWOT Analysis, 2014 34
Table 13: Overall Unmet Needs - Current and Future Level of Attainment 36
Table 14: HPV Vaccines - Phase Pipeline, 2014 53
Table 15: Product Profile - V503 55
Table 16: V503 SWOT Analysis, 2013 60
Table 17: Bivalent Vaccine (Xiamen Innovax) SWOT Analysis, 2014 63
Table 18: Sales Forecasts ($) for HPV Vaccines in Canada, 2012-2022 66
Table 19: Key Events Impacting Sales for HPV Vaccines in Canada, 2012-2022 68
Table 20: Canada HPV Vaccine Market - Drivers and Barriers, 2014 68
Table 21: Key Launch Dates 85
Table 22: Key Patent Expiries 85
Table 23: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 90


Buy a copy of this report @ .


Contact / Call +1 888 391 5441 for further information on “PharmaPoint: Prophylactic Human Papillomavirus Vaccines - Canada Drug Forecast and Market Analysis to 2022report OR for any other market research and intelligence needs you may have for your business.